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Introduction 
Mycobacterium bovis (Mb), the causative agent of 
bovine tuberculosis (bTB), infects cattle and other 
animals, including humans. In this study we found that 
a M. bovis knockout strain in phoP and mce2 operons 
protected C57BL/6 mice against virulent M. bovis 
challenge. The double mutant was significantly more 
attenuated than the parental M. bovis Δmce2 strain in 
immunodeficient mice.  
Bovine tuberculosis is a chronic infectious disease 
caused by Mycobacterium bovis affecting cattle and 
other mammals, including humans. Infection in humans 
occurs when unpasteurized milk (or derivatives) is 
consumed or when people are in contact with infected 
cattle. Zoonotic TB is particularly relevant in many 
developing countries in which the bTB is highly 
prevalent and human populations usually live in close 
contact with domestic and production animals [1-3]. 
Therefore, bTB is a factor that undermines the 
development of the dairy and meat industry and also a 
threat for public health.  
Given that the elimination of TB-cattle is 
economically not affordable in developing countries, 
cattle vaccination may represent an attractive 
intervention strategy to reduce the impact of bTB on 
livestock. To date, however, there is no available 
vaccine against bTB. 
Bacillus Calmette–Guérin (BCG) is the vaccine 
against human tuberculosis. It is a live M. bovis that has 
lost its virulence and has been widely used since 1945. 
However, the efficacy of BCG to protect against 
tuberculosis in humans has shown to be highly variable 
and dependent on different factors, such as the genetic 
of the subject population, environmental factors and the 
BCG substrain diversity [4]. In cattle, vaccination with 
BCG has demonstrated reductions in disease severity 
after experimental challenge with virulent M. bovis 
strains but the protection induced was, in general, not 
complete [5]. Apart of BCG, very few attenuated M. 
bovis strains have been used as experimental vaccine 
against bTB and some of them have shown to confer 
protection against M. bovis challenge in animal models 
[6,7]. In previous studies we reported the development 
of a M. bovis strain deleted in the virulence genes 
mce2A-B, the strain was called MbΔmce2. This strain 
was superior to BCG to protect cattle against bTB [9] 
and was unable to produce tuberculosis in cattle [10], 
which suggests that in cattle this is a safety vaccine. 
However, the Geneva consensus criteria [11] have 
established that TB vaccine must be based on two 
independent stable deletion mutations without 
antibiotic resistance markers. Therefore, to fulfil part of 
the requirements for a live TB candidate vaccine, we 
deleted the phoP virulence gene from MbΔmce2 [12]. 
The election of phoP as gene target for knockout was 
based on the fact that a Mycobacterium tuberculosis 
mutant in the two-component system PhoP-PhoR have 
shown successful results and is the first live attenuated 
M. tuberculosis vaccine to enter in clinical evaluation 
[13]. We then reported that the double knockout in 
phoP-phoR and mce2A/B loci of M. bovis conferred 
protection against virulent M. bovis challenge in 
BALB/c mice [12]. In order to better characterize this 
double M. bovis mutant as bTB vaccine, here we 
evaluated its protection capacity in C57BL/6 mice and 
we compared its attenuation to that of the parental 
strain, M. bovis Δmce2, in immunodeficient BALB/c 
mice. 
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Results and discussion 
The phoP gene (Mb0780), mce2A (Mb0604) and 
mce2B (Mb0605) have been knocked out in M. bovis 
NCTC10772 genome, resulting in single (phoP or 
mce2) and double (phoP and mce2) M. bovis mutants 
[9,10,. When tested in BALB/c mice all vaccine strains, 
including BCG, have showed a reduced bacterial 
burden in organs after M. bovis challenge, as compared 
to non-vaccinated mice [12]. However, MbΔmce2 has 
also been assessed as experimental vaccine in cattle, 
showing better protection than BCG [9]. In this study 
we evaluated the vaccine properties of the double 
MbΔmce2-phoP mutant in C57BL/6 mice. 
Female C57BL/6 mice (5-6 weeks old) were 
immunized subcutaneously with 1.105 colony forming 
units (CFU) in a single dose with BCG or MbΔmce2-
phoP mutant. A group was inoculated with saline 
solution as unvaccinated control.  After 60 days post 
immunization the animals were infected with 5.104 
CFU of virulent M. bovis NCTC 10772 by intratracheal 
instillation as previously described [12]. Thirty days 
after challenge all mice were sacrificed and CFU were 
determined in lungs and spleen. 
As showed in Figure 1, all immunized mice were 
protected compared to the saline control (p <0.01). The 
protection conferred by the MbΔmce2-phoP mutant 
was equivalent to that of BCG in both spleen (Figure 
1A) and lungs (Figure 1B). The fact that MbΔmce2 has 
shown to be more effective than BCG to protect cattle 
[10] but not mice [12] illustrates the limitation of using 
mice to test anti-tuberculosis vaccine candidates. 
However, the mouse is a widely accepted model of TB 
because reproduces the disease in the lungs, is cheaper 
than other alternative models and a large number of 
knock out strains and immunological reagents are 
available for investigation. It has been demonstrated 
that C57BL/6 mice control the TB infection better than 
BALB/c mice [14]. Therefore, the findings of this study 
reinforce the protective attributes of MbΔmce2-phoP in 
a bTB-restrictive environment. 
We next compared the virulence of the double 
MbΔmce2-phoP mutant to that of the single MbΔmce2 
mutant in order to know whether or not the elimination 
of the virulence phoP improves the safety properties of 
the candidate vaccine. For this purpose groups of 
female nude (N:NIH (S)- FoxnInu) BALB/c mice of 6–
8 weeks of age were infected with 50,000 CFUs of M. 
bovis strains and the survival was subsequently 
assessed. The median survival of MbΔmce2-phoP (150 
days) was statistically different (p <0.001) to that of the 
MbΔmce2-infected animals (63 days) (Figure 2). This 
result demonstrates that MbΔmce2-phoP is safer than 
Figure 1. Protection assays of MbΔmce2-phoP in C57BL/6 
mice.  
Groups of 10 mice were vaccinated with 1.105 CFU of BCG or mutant 
strain, and compared with control nonvaccinated animals. 30 days post-
vaccination, mice were challenged by intratracheal route with 50,000 
CFU of M. bovis and one month later the bacterial burden in spleens (A) 
and lungs (B) was determined. Columns show the mean values and error 
bars of CFU/organ. Data were analysed using one-way ANOVA analysis 
and Bonferroni’s post-test. (**p <0.01). 
Survival of nude mice after intratracheal inoculation M. bovis strains 
(5×105). Statistical analysis was performed using Mantel-Cox test. dpi: 
days after infection, CFU: colony forming units. (***p <0.001). 
Figure 2. Virulence assays in nude mice. 
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the highly protective MbΔmce2 vaccine [10]. It also 
confirms the role of PhoP, the transcriptional regulator 
of the two-component system PhoP-PhoR [10,7], in the 
virulence of M. bovis in immunodeficient mice. 
 
Conclusion 
Here we confirm the efficacy of MbΔmce2-phoP to 
protect mice against bTB challenge and we 
demonstrated that this new attenuated strain is safer 
than our previous bTB vaccine MbΔmce2. Altogether 
these results support the further assessment of this 
candidate in cattle model of bTB. 
Experiments with mice were performed in 
compliance with the regulations of the Institutional 
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